News

Bausch + Lomb advances dual-action dry eye drop to phase 3 and reports positive phase 1b data for TRPV1 antagonist BL1332

Angela Y. Zhu, MD, of Bascom Palmer Eye Institute, explains how to distinguish eye allergy from vision-threatening VKC and AKC in children and when steroid-sparing therapy and referral are warranted.

The over-the-counter lens is the first FDA-recognized device in its class, targeting light sensitivity in patients with episodic migraine aged 12 and older.

Large cohort links long-term tadalafil for urinary symptoms to modestly higher open-angle glaucoma risk.

A new study reported that the so-called “high-pillow sleeping position” can result in elevated intraocular pressure (IOP) values and decreased ocular perfusion pressure (OPP) in patients with glaucoma compared with sleeping in the supine position.

Amy Zhang, MD, on why self-care alone won't fix physician burnout and what health systems need to address instead.

Alice Epitropoulos, MD, shares cases of Demodex blepharitis and reflects on how lotilaner has changed treatment before ocular surgery.

Topical chloroprocaine hydrochloride ophthalmic gel 3% (IHEEZO, Harrow) resulted in less pain f following intravitreal injections in patients undergoing same-day bilateral intravitreal injections.

The Aug. 20-23 meeting in Monterey, California, offers CME across subspecialties alongside sessions on mentorship, career longevity, and research.

Amy Zhang, MD, on the ergonomic habits and equipment changes that protect ophthalmic surgeons' careers long-term.

The FDA issued a recall notice for an eye drop designed to relieve ocular redness, itching, burning, and watery eyes. The Class II recall alerts consumers and physicians to possible temporary or reversible health effects, but serious harm is unlikely.

Neel S. Vaidya, MD, MPH, MBA, on why keratoconus can progress aggressively in children and teens—and how early topographic screening and prompt crosslinking protect long-term vision.

CMS payment rates for the FSYX Ocular Pressure Adjusting Pump take effect October 1, 2026, clearing a reimbursement path for the noninvasive glaucoma device.

Host Deborah G. Ristvedt, DO, welcomes Dr. Berdahl to discuss the formative experiences, entrepreneurial drive, and personal philosophy that have shaped his career as a surgeon, innovator, and mentor.

AI accelerates retina trials and imaging insights, boosts screening access, and raises urgent questions on regulation, privacy, and equity.

The Jack McGovern Coats' Disease Foundation has announced the initiation of new research to develop the first validated animal model of Coats' Disease, a rare eye disorder that primarily affects children.

A roundup of Ophthalmology Times' H1 2026 refractive coverage shows the field moving toward individualized care through adjustable lens outcomes, AI-assisted planning, and refined pediatric myopia monitoring.

Approach centers on pressure-free messaging and optometric education

Patient enrollment is complete in a phase 3 registrational, or pivotal, trial to evaluate OPGx-LCA5, a gene therapy that is under investigation for treating Leber congenital amaurosis type 5-associated inherited retinal disease.

Two investigational pipeline therapies take aim at the root causes of dry eye disease

Noha Ekdawi, MD, FAAP, explains why pediatric myopia demands individualized, progression-based management. She details how they sequence spectacle defocus lenses, low-dose atropine, and specialty contacts; drive long-term adherence; and frame lifetime risk for parents without causing alarm.

Waste, cost, and carbon are converging to reshape how cataract centers choose instruments.

Ahead of his November 10, 2026, start date, the incoming Duke ophthalmology chair shares his vision for research, training, and the integration of AI and data science.

Sight Sciences' newest MIGS device gains FDA clearance for single-pass canaloplasty and trabeculotomy in open-angle glaucoma.

The trial is evaluating the company’s orally administered synthetic cannabinoid, ART27.13

Harrow will acquire Tyrvaya, the only FDA-approved nasal spray for dry eye disease, from Viatris for up to $100 million, complementing its cyclosporine product Vevye.

Capsulotomy size may not be refractive neutral: a larger opening shifted the IOL about 120 µm posteriorly in thin lenses and anteriorly in thick ones in a paired-eye study.

Private practice fellowships sharpen cataract and refractive skills with high volume, new tech, and hands-on practice management mentorship.